Paradigm Biocapital Advisors LP
Q2 2023 13F-HR Holdings
Net value change ($000)
+238,996
(22.6%)
New positions
9
Sold out positions
5
Turnover %
39.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Karuna Therapeutics, Inc. | 61,500 | NEW |
| LEGN | 51,821 | 71.2% |
| NUVL | 47,250 | NEW |
| Ambrx Biopharma Cayman, Inc. | 27,167 | NEW |
| OLMA | 25,424 | 307.5% |
| VIR | 24,879 | NEW |
| IMTX | 22,905 | NEW |
| AUTL | 21,937 | NEW |
| Cerevel Therapeutics Holdings, Inc. | 20,507 | 52.7% |
| IMCR | 20,475 | 36.8% |
Top Reduces (Value $000, Stocks/ETFs)
| BIIB | -97,197 | -100.0% |
| Seagen Inc. | -57,090 | -100.0% |
| KROS | -39,743 | -100.0% |
| ASND | -37,620 | -100.0% |
| VOR | -14,886 | -42.7% |
| ARGX | -12,058 | -17.9% |
| INCY | -5,172 | -5.7% |
| Poseida Therapeutics, Inc. | -3,303 | -100.0% |
| ZLAB | -1,966 | -7.6% |
| ONC | -1,131 | -2.9% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
58,460
(4.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|